News >

Sharman Showcases Frontline Acalabrutinib Activity in CLL

Caroline Seymour
Published: Monday, Dec 16, 2019

Jeff P. Sharman, MD

Jeff P. Sharman, MD

The highly selective BTK inhibitor acalabrutinib (Calquence), either as a single agent or in combination with obinutuzumab (Gazyva), has proven to be a safe and effective treatment option for patients with previously untreated chronic lymphocytic leukemia (CLL), according to Jeff P. Sharman, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x